Long-term quantitative valuation models projecting CRISPR Therapeutics (CRSP) stock out to 2030 suggest potential trading ranges stretching between $155 and over $200 per share, assuming successful pipeline commercialization. However, multi-year biotech projections carry extreme volatility and depend heavily on future regulatory approvals, competitive pressures, and broad macroeconomic market cycles.